ArticleMayo Clinic proceedings. Innovations, quality & outcomes2025
Developing and Deploying a Hypertension Remote Patient Monitoring Program 101.
Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe the development and deployment of a remote patient monitoring (RPM) program for hypertension and to share outcomes from an initial cohort of patients enrolled in this program. Patients and Methods: The development of an RPM program for hypertension is described in detail. A sample of patients who were enrolled in RPM, participated for at least 2 weeks, and completed the program from January 1, 2023, to December 31, 2023, were included in the analysis. Clinical data were summarized using descriptive statistics. For comparing continuous variables, the independent samples Results: Total of 101 patients met the inclusion criteria. The median age was 69 years with a range from 22 to 95 years; 51 (51%) were men, 93 (92%) were White, and 6 (6%) identified as Hispanic. The median length of participation in the program was 38 days, with a range from 18 to 160 days. The average blood pressure decreased during program enrollment from 153/84 to 126/75 mm Hg ( Conclusion: Developing and implementing an RPM program for hypertension is feasible with adequate resources, planning, and piloting. These programs are associated with clinically significant improvements in blood pressure control for patients with hypertension without considerably increasing calls and messages from patients beyond routine care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.